Supriya Lifescience Ltd., a cGMP-compliant active pharmaceutical ingredient (API) manufacturer with operations in more than 120 countries, reported a strong top-line performance in the first quarter of FY27, with revenue increasing by 30.8% year-on-year to ₹189.75 crore.
According to the company’s unaudited financial results, revenue rose from ₹145.07 crore in Q1 FY26 to ₹189.75 crore in Q1 FY27, reflecting sustained demand across key therapeutic segments and continued expansion in international markets.
Despite the significant increase in revenue, profitability remained under pressure. EBITDA stood at ₹47.46 crore compared with ₹51.70 crore in the corresponding quarter of the previous financial year. EBITDA margins declined to 25.0% from 35.6%.
Profit After Tax (PAT) for the quarter was ₹24.04 crore, compared with ₹34.79 crore in Q1 FY26. PAT margins also declined from 24.0% to 12.7%.
The anesthetic segment continued to be the company’s largest therapeutic category, contributing 48% of total revenue during the quarter. Vitamins accounted for 17% of revenue, demonstrating growing demand and a more diversified product portfolio.
Geographically, Asia emerged as the company’s largest market, contributing 39% of total revenue, compared with 32% in the previous year. Europe contributed 35%, while Latin America accounted for 20% of revenue. North America and other international markets contributed 3% each.
Exports remained a key growth driver, accounting for 81% of the company’s total revenue during the quarter. The strong export contribution highlights Supriya Lifescience’s expanding global footprint and diversified customer base.
The company also reported encouraging progress across its product portfolio. Its cardiovascular product, launched in Q3 FY26, continued gaining traction, while the ADHD product recorded strong demand across Latin America and Europe. Additionally, the company’s liquid anesthetic product has been commercialized, with regular monthly supplies already underway.
Looking ahead, Supriya Lifescience plans to launch approximately four new products during FY27, including two products each in the anesthetic and ADHD categories, to further strengthen its pipeline and support future growth.
Manufacturing expansion also remained a strategic priority during the quarter. Capacity utilization stood at 70%, while total reactor capacity reached 932 KLPD across manufacturing facilities.
The company’s Ambernath facility has now commissioned its finished dosage manufacturing capabilities, covering tablets, capsules, liquids, nasal formulations, inhalation products, and injections. Validation and registration batches are currently underway for regulatory submissions.
Supriya Lifescience also continued investing in research and development, with more than 68 scientists working across its API and formulation development programs. Two dedicated R&D centers at Ambernath and Lote have been established as part of the company’s long-term innovation strategy.
Commenting on the quarterly performance, Dr. Satish Wagh, Executive Chairman and Whole-Time Director of Supriya Lifescience Ltd., said that the company remains focused on expanding its product portfolio, strengthening manufacturing and R&D capabilities, and accelerating the commercialization of new products across key therapeutic segments.
With strong export-driven growth, expanding production capacity, and a robust product pipeline, the company remains optimistic about its long-term growth trajectory.
